A New Approach towards Minimizing the Risk of Misdosing Warfarin Initiation Doses
暂无分享,去创建一个
Houshang Darabi | Ashkan Sharabiani | William L. Galanter | Edith Nutescu | W. Galanter | H. Darabi | E. Nutescu | Ashkan Sharabiani
[1] Stephen E Kimmel,et al. Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. , 2008, Pharmacogenomics.
[2] Christine W. Duarte,et al. High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans , 2011, Bioinform..
[3] C. Thorn,et al. Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans , 2008, Clinical pharmacology and therapeutics.
[4] Nianjun Liu,et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. , 2008, Pharmacogenomics.
[5] Valentin Fuster,et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. , 2003, Circulation.
[6] Ashkan Sharabiani. Medical Decision Making for Warfarin Dosing Using Machine Learning Methods , 2016 .
[7] Houshang Darabi,et al. Machine learning based prediction of warfarin optimal dosing for African American patients , 2013, 2013 IEEE International Conference on Automation Science and Engineering (CASE).
[8] Deborah A Nickerson,et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.
[9] Panos Deloukas,et al. The largest prospective warfarin-treated cohort supports genetic forecasting. , 2009, Blood.
[10] Houshang Darabi,et al. Revisiting Warfarin Dosing Using Machine Learning Techniques , 2015, Comput. Math. Methods Medicine.
[11] J N Douglas,et al. Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans , 2013, The Pharmacogenomics Journal.
[12] Julie A. Johnson,et al. Warfarin pharmacogenetics. , 2015, Trends in cardiovascular medicine.
[13] M. Whirl‐Carrillo,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing , 2011, Clinical pharmacology and therapeutics.
[14] Paolo Massimo Buscema,et al. An optimized experimental protocol based on neuro-evolutionary algorithms: Application to the classification of dyspeptic patients and to the prediction of the effectiveness of their treatment , 2005, Artif. Intell. Medicine.
[15] Valentin Fuster,et al. AHA/ACC Scientific StatementAmerican Heart Association/American College of Cardiology Foundation guide to warfarin therapy1 , 2003 .
[16] M. Rieder,et al. Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.
[17] Massimo Buscema,et al. Prediction of optimal warfarin maintenance dose using advanced artificial neural networks. , 2014, Pharmacogenomics.
[18] Mario Plebani,et al. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. , 2011, Pharmacogenomics.
[19] R. Altman,et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.